OBJeCTIve: The term "null cell" adenoma was first proposed in 1980 to designate pituitary adenomas lacking clinical, biochemical and morphological markers to disclose their cell origin. DESIGN: The aim of this study was to investigate the presence of α-and β-gonadotropin subunits in clinically nonfunctioning pituitary tumors, which were initially immunonegative and thus diagnosed as null cell adenomas. for this reason, we reapplied immunohistochemistry using a more sensitive method comprising a tyramide signal amplification technique, combined with a polymer antibody immunohistochemical detection system. ResULTs: With this approach, all these previously negative tumors became positive for α-and β-gonadotropin hormone subunits. CONCLUsIONs: Our results prove that so-called "null cell" adenomas produce α-SU or/and β-FSH or β-LH and therefore are gonadotrph adenomas in origin.
INTRODUCTION
The tern "null cell" adenoma was first proposed by Kovacs et al in 1980 to designate pituitary adenomas lacking clinical, biochemical and morphologic markers, which would permit disclosure of their cellular origin. This original study was based on a series of surgically removed pituitary adenomas, which were unassociated clinically or biochemically with hormone secretion in excess. By immunohistochemistry, a substantial majority of these chromophobic tumors contained no adenohypophysial hormones. Electron microscopy also failed to reveal their morphogenesis. 1 However, in our material only a small subset of nonfunctioning adenomas was immunonegative for all pituitary hormones.
The aim of our study was to reexamine nonfunctioning pituitary adenomas, diagnosed as null cell, which were initially immunonegative for α-and β-subunits of gonadotropin hormones. To investigate gonadotropin hormone production by null cell adenomas, we repeated the immunohistochemistry using advanced techniques, including the sensitive catalyzed tyramide signal amplification (TSA) technique, combined with a polymer antibody containing detection system.
MATeRIAL AND MeThODs
Among 1492 surgically removed pituitary adenomas, collected at the National Pituitary Tumor Reference Center, 51 (3.4%) were chromophobic, PAS-negative and negative for all pituitary hormones, null cell adenomas. In addition, all 51 adenomas were nonfunctioning, since patients harboring these tumors showed no clinical signs or symptoms attributed to GH-, PRL-, ACTH-, or TSH-hypersecretion. For this study, 10 of these adenomas were randomly selected.
The initial diagnosis was based on immunohistochemistry using the standard avidin-biotin-peroxidase (ABC) method, after enzymatic pretreatment with pronase to reveal the hidden antigenic sites. Polyclonal antisera were directed against growth hormone (GH), prolactin (PRL), adrenocortinotropin (ACTH) and β-subunit of thyrotropin hormone (β-TSH), β-follicle stimulating hormone (β-FSH), β-luteinizing hormone (β-LH) and α-subunit of glycoprotein hormone (α-SU). The working dilutions ranged from 1:200 to 1:2.000. All antisera were provided by the National Hormone and Peptide Program (NHPP, Torrance CA, USA). Details of the method were described previously. 2 In the current study, immunohistochemistry was repeated using the same pretreatment with pronase and the same dilutions for all pituitary hormone antisera. The next day, sections were treated with a signal amplification system, comprising peroxidase catalyzed deposition of biotinylated TSA kit (Dako A/S, Glostrup Denmark), followed by the one-step EnVision polymer detection system (Dako A/S, Glostrup Denmark) as a secondary link to DAB chromogen. 3, 4 Two sets, each one of 7 sections from gonadotroph adenomas, known as positive for β-FSH β-LH and α-SU and negative for the remaining hormones (GH, PRL, β-TSH and ACTH), served as controls. They were immunostained together with the study group of the 10 null cell adenomas followed by TAS and detection system procedures. Sections from the first set immunostained with the 7 pituitary hormone antisera served as positive controls. Sections of the second set, where the primary antisera were substituted by buffer solution, served as negative controls.
For electron microscopy, samples from the adenomas were fixed in glutaraldehyde, postfixed in osmium tetroxide and embedded in Epon-Araldite. Ultrathin sections stained with uranyl acetate and lead citrate were examined on either a Philips 300 or a 410-LS electron microscope. 
ResULTs

Immunohistochemical studies
After application of the TSA technique, all 10 tumors became positive for pituitary α-and β-gonadotropin hormone subunits. The immunoreactivity was heterogeneous regarding the distribution, extent and staining intensity ( Figure 1 ). Immunostains were diffuse in the cytoplasm, often with enhancement along cytoplasmic membranes ( Figure 2 ). In some tumors, the attenuated cytoplasmic processes of adenoma cells were highlighted. In addition, the immunoreactivity in several cells of the positive control specimens of gonadotroph adenomas that was previously mild to moderate became more intense (Figure 3 ). Immunostains were negative for the remaining pituitary hormones (GH, PRL, ACTH and β-TSH) in all studied cases and positive controls. Negative controls were immunonegative for all pituitary hormones.
Electron microscopic studies:
All adenomas demonstrated poorly developed cytoplasmic membranous organelles including a few scattered lamellar arrays of rough endoplasmic reticulum and Golgi apparatus saccules. The cytoplasm contained sparse and small secretory granules measuring up to 200 nm in some tumors with a tendency to distribution along cytoplasmic membranes. The number and volume density of cytoplasmic mitochondria was variably increased.
DIsCUssION
By definition, adenomas unassociated with signs and clinical symptoms are classified as nonfunctioning or silent; the latter are immunoreactive for pituitary hormones, which are responsible for endocrine syndromes. Up to 30-35% of adenohypophysial tumors are nonfunctioning macroadenomas, currently representing the most common in both clinical and surgical series. They present with mass effect symptoms and hypopituitarism. 5 They comprise a heterogeneous group of adenohypophysial tumors, consisting mostly of chromophobic null cell and gonadotroph adenomas. The remaining unusual types include the silent GH-, PRL-and TSH-producing adenomas, the silent corticotroph adenomas subtype 1 and 2 and the rare acidophil stem cell adenoma and silent subtype 3 plurihormonal adenoma. 6, 7 Null cell and gonadotroph adenomas share similarities in histology and ultrastructure. By histology, they are chromophobic and PAS negative tumors consisting of small ovoid or polar shaped cells, often with perisinusoidal arrangement and pseudo-rosette formation. By electron microscopy they show variablydeveloped rough endoplasmic reticulum and Golgi apparatus saccules and contain small and sparse secretory granules measuring up to 200nm. Based on the abundance of accumulated mitochondria, they are divided into oncocytic (oncocytomas) and nononcocytic tumors. However, this distinction is not of clinical relevance. 6 The original designation coined by Kovacs et al in 1980 of "null cell" adenomas was based on 56 nonfunctioning tumors among 343 surgically removed pituitary adenomas. Based on the perosidase-antiperoxidase immunoenzymatic (PAP) immunohistochemical method, they contained no adenohypophysial hormones, although electron microscopy showed sparse and small secretory granules. 1 However, later studies have definitely shown that null cell adenomas release β-FSH or β-LH in dispersed cell tissue cultures. 9, 10, 11 More advanced molecular studies carried out via Northern blot technique 12, 13 and by in situ hybridization. [14] [15] [16] have shown that they may express mRNA of α-and/or β-FSH or β-LH.
Gonadotroph adenomas were thought to be very rare in the past, particularly before application of immunohistochemistry. 17, 18 In a detailed comparative study of 300 null cell adenomas, oncocytomas and gonadotroph adenomas were analyzed by immunohistochemistry for gonadotropin hormone subunits. It was found that at least 23% of tumors initially diagnosed as null cell adenomas and 28% as oncocytomas could be considered gonadotroph adenomas. 8 By electron microscopy, some of these adenomas showed tiny secretory granules along cytoplasmic membranes, often accumulating in the attenuated cytoplasmic processes. These findings, originally described in TSH-secreting adenomas and referred to as "a sign of glycoprotein hormone cell differentiation", can be observed in gonadotroph adenomas as well. In this study the authors concluded: "...the ever constricted category of null cell adenoma will someday find as little place in the nosology of pituitary adenomas as does the term chromophobic adenoma". It was therefore speculated that null cell and gonadotroph adenomas belong to the same entity. 8 During the last two decades, advanced immunohistochemical techniques utilizing more sensitive detection systems such as ABC have replaced the classic PAP method. This technique, in conjunction with pretreatment with proteolytic digestion to retrieve the hidden antigenic sites due to fixation in formalin, has led to more frequent detection of gonadotropin hormone subunits. 8 More recently, the EnVision detection system, a peroxidase-conjugated polymer backbone, which also carries secondary antibody molecules directed against rabbit and mouse immunoglobulins, was introduced. The main advantages of this system include high sensitivity for routine immunohistochemistry and elimination of background staining. 18 As a result, among clinically nonfunctioning pituitary adenohypophysial tumors, the diagnosis of null cell adenoma gradually diminished in favor of gonadotroph adenoma. 8, 18, 19 Meanwhile, catalyzed signal amplification systems such as TSA were introduced as a complementary system to improve immunohistochemistry. 20 Sanno et al (1996) have demonstrated that the latter technique is extremely sensitive. 21, 22 In their studies detecting gonadotropin subunits in gonadotroph cells of normal pituitaries, they have noted that catalyzed signal amplification systems are 1000-fold more sensitive than the standard indirect PAP method and 100-fold more than the standard ABC method. 22 In the present study, we first applied the TSA technique combined with a secondary polymer antibody containing detection EnVision system to detect pituitary hormones. We were able to detect gonadotropin subunits in all adenomas that were initially completely immunonegative and thus reported as null cell adenomas. Therefore, we were able to reclassify them as gonadotroph adenomas.
In the original paper introducing the term "null cell" adenoma, the authors stated: "…with increasing knowledge, appropriate markers will be found and, with the use of more sophisticated methodology currently unavailable, the number of diagnosed null cell adenoma cases will diminish". 1 The reason that null cell adenomas were negative for gonadotropin hormone subunits is mostly attributed to the low sensitivity of immunohistochemical systems that were not sufficient to detect the low amount of protein hormones stored within the sparse and tiny secretory granules. Therefore, routine immunohistochemistry, even after pretreatment with proteolytic digestion, was not adequate to detect gonadotropin hormone subunits in all cases. Another problem related to the reproducibility of immunohistochemistry is the selection of antibodies used. Obviously, monoclonal antibodies have high specificity but low sensitivity. In contrast, polyclonal antisera are very sensitive, although they might show cross-reactivity for other pituitary hormones. In the current study, given that adenomas were selectively positive for gonadotropin hormone subunits and negative for all remaining pituitary hormones, the problem of specificity is beyond any further discussion.
In conclusion, using currently available advanced and sensitive immunohistochemical protocols, we were able to prove that so-called "null cell" adenomas produce α-or/and β-FSH or β-LH subunits and thus are gonadotroph adenomas in origin. We therefore suggest that the term gonadotroph be applied to any adenoma positive for α-SU or/and β-LH or β-FSH, and negative for GH, PRL, ACTH and β-TSH, irrespective of the number of immunoreactive cells and of staining intensity. However, the term "null cell" adenoma should be reserved for routine diagnosis when immunohistochemistry is negative for all pituitary hormones.
